文献速递传染病防控与疫情报告免疫规划

灭活疫苗与RNA颗粒疫苗对鸡北美分支2.3.4.4b H5高致病性禽流感病毒的效力

Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
PubMed 文献 · Vaccine · 2023-11-04

研究评估了三种疫苗在鸡体内对抗北美分支2.3.4.4b H5高致病性禽流感病毒(A/turkey/Indiana/3703-003/2022 H5N1)的效力:两种灭活疫苗(重组H5N1和SEP-22-N9)和一种甲病毒RNA颗粒疫苗。所有疫苗均提供100%保护免于死亡和发病,并显著减少口咽和泄殖腔排毒,但不同疫苗在攻毒后2天和4天的排毒量存在差异。免疫后7天,RNA颗粒疫苗组100%鸡的血清中检测到神经氨酸酶抗体,SEP-22-N9组为70%。

要点

  • 所有三种疫苗均提供100%保护,使鸡免于死亡和发病。
  • 所有疫苗均显著减少口咽和泄殖腔排毒,但攻毒后2天和4天排毒量存在组间差异。
  • 攻毒后7天,RNA颗粒疫苗组100%鸡和SEP-22-N9组70%鸡的血清中检测到神经氨酸酶抗体。

核心结论

  • 三种疫苗(rgH5N1、RNA颗粒疫苗和SEP-22-N9)均提供100%保护,显著减少病毒排毒,但排毒量存在差异;接种后可通过检测神经氨酸酶或核蛋白抗体识别感染鸡。

研究设计与样本

  • 评估三种疫苗在鸡体内对抗北美分支2.3.4.4b H5 HPAIV(A/turkey/Indiana/3703-003/2022 H5N1)的效力,疫苗包括:1)商业灭活反向遗传H5N1产品(rgH5N1),含分支2.3.4.4c H5血凝素;2)商业甲病毒RNA颗粒疫苗,含TK/IN/22 HA;3)自制灭活反向遗传疫苗,含TK/IN/22 HA和北美谱系N9神经氨酸酶(SEP-22-N9)。两种灭活疫苗的HA基因被修饰为低致病性,其余基因来自PR8流感毒株。

主要发现

  • 所有疫苗均提供100%保护免于死亡和发病,与模拟接种组相比显著减少口咽和泄殖腔排毒;攻毒后2天和4天,不同疫苗的排毒量存在差异;攻毒后7天,ELLA检测显示RNA颗粒疫苗组100%鸡和SEP-22-N9组70%鸡的血清中神经氨酸酶抗体阳性;商业ELISA在RNA颗粒疫苗组每个时间点均检测到超过50%鸡的核蛋白抗体。

关键数值与推荐

  • 所有疫苗对死亡和发病的保护率为100%。
  • 与模拟接种组相比,所有疫苗均显著减少口咽和泄殖腔排毒。
  • 攻毒后7天,ELLA检测神经氨酸酶抗体:RNA颗粒疫苗组100%鸡阳性,SEP-22-N9组70%鸡阳性。
  • 商业ELISA检测核蛋白抗体:RNA颗粒疫苗组每个时间点超过50%鸡阳性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Highly pathogenic avian influenza virus (HPAIV) has caused widespread outbreaks in poultry in the Americas. Because of the duration and extent of these outbreaks, vaccine use may be an additional tool to limit virus spread. Three vaccines were evaluated for efficacy in chickens against a current North American clade 2.3.4.4b H5 HPAIV isolate, A/turkey/Indiana/3703-003/2022 H5N1. The vaccines included: 1) a commercial inactivated reverse genetics (rg) generated H5N1 product with a clade 2.3.4.4c H5 hemagglutinin (HA) (rgH5N1); 2) a commercial alphavirus RNA particle (RP) vaccine with the TK/IN/22 HA; and 3) an in-house inactivated rg produced vaccine with the TK/IN/22 HA and a North American lineage N9 neuraminidase (NA) (SEP-22-N9). Both inactivated vaccines were produced with HA genes that were modified to be low pathogenic and with the remaining genes from the PR8 influenza strain. All vaccines provided 100% protection against mortality and morbidity and all vaccines reduced virus shed by the oropharyngeal and cloacal routes significantly compared to sham vaccinates. However, differences were observed among the vaccines in quantities of virus shed at two- and four-days post challenge (DPC). To determine if infected birds could be identified after vaccination to aid surveillance programs, serum was collected from the RP and SEP-22-N9 vaccine groups at 7, 10, and 14 DPC to detect antibody to the NA and nucleoprotein (NP) of the challenge virus by enzyme linked lectin assay (ELLA) and ELISA. As early as 7DPC ELLA detected antibody in sera from 100% of the chickens in the RP vaccinated group and 70% of the chickens in the SEP-22-N9 vaccinated group. Antibody to the NP was detected by commercial ELISA in more than 50% of the birds in the RP vaccinated group at each time point.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Spackman E, Suarez DL, Lee CW, et al. Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens. Vaccine. 2023. PMID: 37932132. doi:10.1016/j.vaccine.2023.10.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。